Uncategorized
Triple therapy reduces frequency, cost of neovascular AMD treatment
Triple combination therapy for neovascular age-related macular degeneration reduced the treatment burden and was more cost-effective than monotherapy, according to a study.The addition of oral zeaxanthin to triple combination therapy further reduced the frequency of treatment and may have lowered the risk for choroidal neovascularization in fellow eyes, the study authors reported.